David Chang, WuXi AppTec

A 'love sto­ry': WuXi AppTec wraps UK-based CRO in­to its cell and gene ther­a­py unit

When WuXi AppTec, one of Chi­na’s largest con­tract re­search or­ga­ni­za­tions, start­ed work­ing with UK-based Ox­gene about a year ago, it was “love at first sight,” CEO David Chang jokes.

Ox­gene, a rough­ly decade-old CRO fo­cused on scal­able gene ther­a­py tech, be­gan li­cens­ing some of their plas­mid work to WuXi just over a year ago. And when that pi­lot went well, WuXi ex­pressed in­ter­est in in­vest­ing, Ox­gene CEO Ryan Ca­wood said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.